NURPF (Neuren Pharmaceuticals) Dividend Yield %: 0.00% (As of Jun. 26, 2026)


NURPF Neuren Pharmaceuticals Ltd NURPF
49 GF Score
Price $9.27
GF Value $4.40
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Neuren Pharmaceuticals Dividend Yield %?

Neuren Pharmaceuticals NURPF +6.67% 49 Dividend Yield % is 0.00% as of Jun. 26, 2026. GuruFocus rates NURPF with a GF Score™ of 49/100 and a GF Value™ of $4.40 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 151 Biotechnology companies, Neuren Pharmaceuticals ranks worse than 662250.99% on this metric.

As of today (2026-06-26), the Trailing Annual Dividend Yield of Neuren Pharmaceuticals is 0.00%.

The historical rank and industry rank for Neuren Pharmaceuticals's Dividend Yield % or its related term are showing as below:

NURPF's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.53
* Ranked among companies with meaningful Dividend Yield % only.

Neuren Pharmaceuticals's Dividend Payout Ratio for the six months ended in Dec. 2025 was 0.00.

As of today (2026-06-26), the Forward Dividend Yield % of Neuren Pharmaceuticals is 0.00%.

Neuren Pharmaceuticals's Dividends per Share for the six months ended in Dec. 2025 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.


Neuren Pharmaceuticals  (OTCPK:NURPF) Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Neuren Pharmaceuticals Dividend Yield % Related Terms


Neuren Pharmaceuticals Dividend Yield % Historical Data

* Premium members only.

The historical data trend for Neuren Pharmaceuticals's Dividend Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuren Pharmaceuticals Dividend Yield % Chart

Neuren Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Dividend Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Neuren Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Dividend Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NURPF vs VRTX, REGN, ALNY: Dividend Yield % Comparison

For the Biotechnology subindustry, Neuren Pharmaceuticals's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neuren Pharmaceuticals Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuren Pharmaceuticals's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Neuren Pharmaceuticals's Dividend Yield % falls into.


NURPF
49GF Score
Neuren Pharmaceuticals Ltd NURPF
Dividend Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neuren Pharmaceuticals Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Frequently Asked Questions Learn more about Dividend Yield % →
What does a Dividend Yield % of 0.00% mean?
Neuren Pharmaceuticals (NURPF) has a Dividend Yield % of 0.00% as of Jun. 26, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Neuren Pharmaceuticals and its competitors. According to the industry distribution chart, Neuren Pharmaceuticals ranks #999999 out of 151 companies in the Biotechnology industry.
Is Neuren Pharmaceuticals' Dividend Yield % too high?
Neuren Pharmaceuticals' current Dividend Yield % is 0.00%. Based on the distribution chart, Neuren Pharmaceuticals ranks #999999 out of 151 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Neuren Pharmaceuticals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuren Pharmaceuticals' Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neuren Pharmaceuticals ranks #999999 out of 151 companies for Dividend Yield %. This places Neuren Pharmaceuticals in the lower half of its industry. The industry median Dividend Yield % is 1.53. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Biotechnology company?
The median Dividend Yield % among Biotechnology companies is 1.53, based on 151 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Neuren Pharmaceuticals and its competitors. For the Biotechnology industry, the median Dividend Yield % is 1.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuren Pharmaceuticals's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuren Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Neuren Pharmaceuticals (NURPF) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.40, compared to a current price of $9.27 — trading 110.7% above its estimated fair value. The current Dividend Yield % is 0.00%. Neuren Pharmaceuticals' overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Neuren Pharmaceuticals (NURPF), the current Dividend Yield % is 0.00% as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neuren Pharmaceuticals (NURPF) Overvalued in 2026?

Based on GuruFocus' analysis, Neuren Pharmaceuticals stock appears to be overvalued. The current stock price of $9.27 is trading 110.7% above its estimated GF Value™ of $4.40. GuruFocus considers Neuren Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for NURPF:

  • Dividend Yield %: 0.00%
  • GF Value™: $4.40 vs. price of $9.27 (110.7% above fair value)
  • GF Score™: 49/100 with 2 warning signs

No single metric tells the full story. See the NURPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Neuren Pharmaceuticals Business Description

Other Exchanges NK9:GermanyNEU:Australia
Address 117 Camberwell Road, Suite 1.01, Hawthorn East, Melbourne, VIC, AUS, 3123
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
49GF Score

Get the complete analysis for NURPF

Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.27
Price
$4.40
GF Value